CSL (OTCMKTS:CSLLY) Trading Up 23.5% – Here’s What Happened

CSL Limited Sponsored ADR (OTCMKTS:CSLLY)’s share price traded up 23.5% on Wednesday . The company traded as high as $29.71 and last traded at $29.59. Approximately 38,875 shares changed hands during trading, a decline of 91% from the average session volume of 411,140 shares. The stock had previously closed at $23.95.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Jefferies Financial Group lowered CSL from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 29th. Canaccord Genuity Group lowered CSL from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Zacks Research upgraded CSL from a “strong sell” rating to a “hold” rating in a research note on Friday, August 7th. Finally, Citigroup downgraded shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Five research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has an average rating of “Hold”.

CSL Price Performance

The company has a 50-day moving average price of $21.80 and a 200-day moving average price of $26.80. The company has a current ratio of 2.57, a quick ratio of 1.15 and a debt-to-equity ratio of 0.51.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.